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INTRODUCTION
Fracture is a serious complication that often occurs in ad-
vanced chronic kidney disease (CKD) patients, causing pa-
tients to often become bed-ridden (or have restricted ambula-
tion) for a long time, and it also has detrimental effects on 
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clinical outcomes and quality of life. The effect of mild to mod-
erate renal dysfunction on increased fracture risk is consid-
ered controversial, although it has been verified in a few stud-
ies recently.1-4 The risks of fracture are known to be influenced 
by both quantity and quality of bone.5 Bone biopsy is a stan-
dard method in order to diagnose bone quality and type of 
CKD-mineral bone disorder (MBD). However, due to its inva-
siveness, bone biopsy is not used frequently in clinical set-
tings. Even though bone mineral density (BMD) is a useful 
tool for evaluating bone quantity and fracture risk in the gen-
eral population, its application in CKD patients has been lim-
ited, as it has been shown that low BMD cannot predict risk of 
fracture in renal failure patients.6 Despite controversy sur-
rounding BMD, recent studies have shown that CKD patients 
who experienced fracture had low bone mass in meta-analy-
sis7 and osteoporosis assessed by dual-energy X-ray absorpti-
ometry (DXA) can predict fracture risk in patients with CKD.8,9 
These results suggest that BMD can serve as an alternative 
surrogate marker for fracture risk in CKD patients.
Renal clearance tests using inulin or inulin analogs are the 
gold standard for measuring glomerular filtration rate (GFR). 
However, difficulties during the infusion procedure and risks of 
anaphylactic allergic reactions limit its routine clinical appli-
cation. In addition, creatinine clearance rate calculated from 
24-hour urine collection can estimate renal function. Howev-
er, it is not convenient to collect urine specimens throughout 
a day. Clinically, serum creatinine levels are used to estimate 
renal function, although the accuracy of this approach is easi-
ly affected by individual muscle mass variations and renal tu-
bular secretion levels. On the other hand, a recent study has 
presented cystatin C as a more valid marker for renal function 
estimation, overcoming the limitations of serum creatinine.10 
Several equations have been formulated to calculate estimated 
GFR (eGFR): Modification of Diet in Renal Disease (MDRD),11 
CKD-Epidemiology Collaboration (CKD-EPI) creatinine 
(CKD-EPI-Cr),12 and CKD-EPI cystatin C (CKD-EPI-Cys).10
Cystatin C is known to be an effective marker of adverse out-
comes in CKD patients, such as coronary artery disease, heart 
failure, and stroke.13-15 In addition, previous research has re-
vealed that cystatin C acts as an inhibitor of bone resorption 
in vitro16 and that it possibly reflects hip fracture risks in older 
women.17 In light of this, we hypothesized that cystatin C-based 
eGFR might be more precisely correlated with loss of bone 
mass than creatinine-based eGFR. Among the eGFR methods 
described above, we aimed to identify the formula that would 
be optimal for correlating osteopenia in CKD patients by mea-
suring BMD by DXA.
MATERIALS AND METHODS
Ethics
This study was performed in accordance with the Declaration 
of Helsinki. It was approved by the Institutional Review Board 
at each participating hospital: Gachon University Gil Medical 
Center (GIRBA2553), The Catholic University of Korea Seoul 
St. Mary’s Hospital (KC11OIMI0441), Kangbuk Samsung Hos-
pital (2011-01-076), Seoul National University Bundang Hos-
pital (B-1106/129-008), Seoul National University Hospital 
(1104-089-359), Seoul Eulji Hospital (201105-01), Severance 
Hospital (4-2011-0163), Inje University Busan Paik Hospital 
(11-091), and Chonnam National University Hospital (CNUH-
2011-092). Written informed consent was provided by every 
participant in the study.
Study design and population
This study was cross-sectional in design, using patient-based 
cohort data from the KoreaN cohort study for Outcome in pa-
tients With Chronic Kidney Disease (KNOW-CKD) study.18 
KNOW-CKD study was performed over 5 years, from 2011 to 
2015, and enrolled 2450 CKD patients at nine university hospi-
tals in Korea. In the present study, we included only 1529 CKD 
patients who were enrolled until December 2013. In this 
study, we could not obtain Z-score data from BMD. Male pa-
tients aged <50 years and pre-menopausal female patients 
were not suitable to diagnose osteopenia with only T-score 
data. The mean age of menopause in Korean women is 49.7 
years old;19 therefore, we excluded patients aged <50 years 
(n=527). The patients who had missing data on cystatin C lev-
els (n=169) or BMD T-scores (n=53) were also excluded. Fi-
nally, 780 patients were included in the study.
Data collection
All data analyzed in this study were collected at study enroll-
ment. Baseline demographic data included age, gender, body 
mass index (BMI), smoking status, blood pressure, and medi-
cal histories, such as diabetes mellitus, hypertension, coro-
nary artery disease, cerebrovascular disease, and congestive 
heart failure. Laboratory data included complete blood cell 
counts, blood urea nitrogen levels, serum creatinine and cys-
tatin C levels, calcium and phosphate concentrations, lipid 
profiles, albumin levels, intact parathyroid hormone levels, 
25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concen-
trations, and C-reactive protein levels. We collected 24-hour 
urine specimens to analyze daily urine protein and creatinine 
levels. Other methodological issues were described in our 
previous study.18
Creatinine and cystatin C measurement 
and eGFR formula
Serum creatinine levels were measured using an isotope dilu-
tion mass spectrometry (IDMS)-traceable method at a central 
laboratory, and cystatin C concentration was assessed by im-
munonephelometry calibrated against the reference. We com-
pared three eGFR methods in this study: four-variable MDRD 
by IDMS-traceable method (MDRD), creatinine-based CKD-
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EPI (CKD-EPI-Cr), and cystatin C-based CKD-EPI (CKD-EPI-
Cys). The formulas were taken from previous studies10-12 and 
are described in Supplementary Table 1 (only online). Addition-
ally, we calculated eGFR using Korean-specific equations to 
compare with CKD-EPI-Cys formula (Supplementary Table 1, 
only online).20
BMD measurement
BMD was measured at baseline by DXA, and total hip and fe-
mur neck T-scores were used to diagnose osteopenia. Spine 
BMD measurement can be misleading if there are anatomical 
abnormalities in the bone, extensive osteophyte formation, or 
aortic calcifications, thus we excluded L-spine T-score data in 
the analysis. The T-score was expressed as the number of stan-
dard deviations of the BMD based on the mean value of a 
healthy, 30-year-old individual of the same gender and eth-
nicity as the patient. Osteopenia was defined as a T-score un-
der -1.0 at two pre-defined points (total hip and femur neck). 
According to the definition of osteopenia, we divided the pa-
tients into two groups: the normal bone mass group (T-score 
>-1.0) and the osteopenia group (T-score ≤-1.0).
Statistical analyses
We performed statistical analyses using IBM SPSS for Windows, 
version 21 (IBM Corporation, Armonk, NY, USA). Numerical 
variables were expressed either as means±standard devia-
tions for data with standard normal distributions or as medi-
ans (interquartile range) for skewed data. Categorical vari-
ables were expressed as numbers (percentages). We analyzed 
the differences between the groups using Student’s t-test or 
the Mann-Whitney U test for continuous variables and the 
chi-squared test for categorical variables. Multiple logistic re-
gression analyses were performed to verify independent fac-
tors related to osteopenia after adjusting for confounding 
variables. Receivers operating characteristic (ROC) curves 
were created for the eGFR calculation methods, and area un-
der ROC curves (AUCs) were compared to identify the eGFR 
equation best correlated with osteopenia according to the 
method of DeLong, et al.21 Analyses related to ROC curves were 
performed using MedCalc® for Windows, version 14.8.1 (Med-
Calc Software, Ostend, Belgium). To make up for the difference 
of baseline renal function between normal bone mass group 
and osteopenia group, we conducted 1:1 propensity score 
matching (PSM) analysis according to the baseline CKD stage 
using IBM SPSS for Windows, version 23 (IBM Corporation).
RESULTS
Characteristics of the study subjects
Baseline demographic and laboratory data of all patients are 
presented in Table 1. Among a total of 780 patients, the mean 
age was 61.0±7.0 years and 291 (37.3%) were female. When 
the patients were classified into groups according to CKD stage, 
the CKD stage 3 (42.7%) and stage 4 (29.4%) groups were the 
largest. In the entire cohort, 185 (23.7%) patients had osteope-
nia at the total hip and 312 (40.0%) at the femur neck. At both 
pre-defined points, the proportion of female patients was high-
er among the osteopenia patients, and the osteopenia pa-
tients were generally older and had lower mean BMIs. The pa-
tients in the normal bone mass group mainly had CKD stages 
1 to 3, although the osteopenia group predominantly included 
CKD stage 4 and 5 patients. Co-morbid conditions were not 
statistically different between the two groups. With respect to 
laboratory data, the osteopenia group had higher blood urea 
nitrogen and cystatin C concentrations and lower mean eGFR 
levels than the normal bone mass group. However, serum cre-
atinine levels in the osteopenia group were not higher, and 
the total hip osteopenia group showed statistically lower mean 
serum creatinine concentrations than the normal bone mass 
group for the total hip. In addition, serum calcium, 25-hy-
droxyvitamin D, and 1,25-dihydroxyvitamin D levels were 
lower in the osteopenia group; however, serum phosphate and 
intact parathyroid hormone levels were higher in the osteope-
nia group. Furthermore, 24-hour urine creatinine levels were 
lower in the osteopenia group for both total hip and femur 
neck osteopenia groups, and 24-hour urine protein concen-
trations were not significantly different between the two 
groups.
eGFR as an independent factor associated 
with osteopenia
To identify the relationship between eGFR and osteopenia, 
multiple logistic regression analysis was performed using 
three models. All three models showed that eGFR calculated 
by CKD-EPI-Cys was independently associated with osteope-
nia at the total hip after adjusting for confounding variables 
[odds ratio (OR) 0.98, 95% confidence interval (CI) 0.97–0.99, 
p=0.004] (Table 2). Similarly, eGFR calculated by CKD-EPI-Cys 
showed comparable results for osteopenia at the femur neck 
(OR 0.98, 95% CI 0.98–0.99, p=0.001). However, the models 
using creatinine-based eGFR data showed discordant results 
between total hip and femur neck assessments. Osteopenia at 
the femur neck correlated with results determined using cre-
atinine-based eGFR methods (MDRD, CKD-EPI-Cr); results 
at the total hip, however, were not related to those determined 
using creatinine-based eGFR formulas (MDRD, CKD-EPI-Cr) 
(Supplementary Table 2 and 3, only online).
Comparison of osteopenia AUCs depending 
on eGFR formulas
We plotted three ROC curves to illustrate the relationship be-
tween osteopenia and eGFR and compared the AUCs to de-
termine which eGFR calculation was best correlated with os-
teopenia in CKD patients. Among the methods, CKD-EPI-Cys 
had the largest AUC at the total hip (AUC 0.678, vs. MDRD, 
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p<0.001; vs. CKD-EPI-Cr, p=0.001) (Table 3) (Supplementary 
Fig. 1, only online). At the femur neck, CKD-EPI-Cys also 
showed similar trends when we compared the AUC thereof 
with those of the other eGFR formulas (AUC 0.665, vs. MDRD, 
p=0.008; vs. CKD-EPI-Cr, p=0.011) (Table 3) (Supplementary 
Fig. 2, only online). The data comparing AUCs of Korean-spe-
Table 1. Baseline Demographic and Laboratory Data
Total
 (n=780)
Total hip Femur neck
Normal
 (n=595)
Osteopenia 
(n=185)
p value
Normal 
(n=468)
Osteopenia 
(n=312)
p value
Age (yr) 61.0±7.0 60.3±6.9 63.3±6.7 <0.001 59.9±6.7 62.6±7.1 <0.001
Female (%) 291 (37.3) 183 (30.8) 108 (58.4) <0.001 127 (27.1) 164 (52.6) <0.001
Body mass index (kg/m2) 24.5±3.0 24.8±2.9 23.5±3.0 <0.001 24.8±2.9 23.9±3.0 <0.001
CKD stage <0.001 <0.001
Stage 1 40 (5.1) 36 (6.1) 4 (2.2) 31 (6.6) 9 (2.9)
Stage 2 111 (14.2) 96 (16.1) 15 (8.1) 78 (16.7) 33 (10.6)
Stage 3 333 (42.7) 268 (45.0) 65 (35.1) 219 (46.8) 114 (36.5)
Stage 4 229 (29.4) 159 (26.7) 70 (37.8) 119 (25.4) 110 (35.3)
Stage 5 67 (8.6) 36 (6.1) 31 (16.8) 21 (4.5) 46 (14.7)
eGFR
MDRD (mL/min/1.73 m2) 41.8±23.5 44.4±23.8 33.7±20.5 <0.001 46.1±23.9 35.5±21.5 <0.001
CKD-EPI-Cr (mL/min/1.73 m2) 43.5±24.7 46.2±25.0 34.7±21.5 <0.001 48.0±24.9 36.7±22.8 <0.001
CKD-EPI-Cys (mL/min/1.73 m2) 44.6±25.4 48.1±26.2 33.3±19.0 <0.001 50.1±26.3 36.4±21.7 <0.001
Bone mineral density
T-score at total hip 0.0±1.3 0.5±0.9 -1.7±0.6 <0.001 0.7±0.9 -1.2±0.8 <0.001
T-score at femur neck -0.6±1.3 -0.1±1.0 -2.1±0.7 <0.001 0.3±0.9 -1.8±0.6 <0.001
Comorbidities
Diabetes mellitus 326 (42.3) 245 (41.7) 81 (44.0) 0.662 193 (42.0) 133 (42.8) 0.251
Hypertension 734 (95.2) 560 (95.4) 174 (94.6) 0.664 439 (95.4) 295 (94.9) 0.712
Coronary artery disease 87 (11.3) 67 (11.4) 20 (10.9) 0.518 54 (11.7) 33 (10.6) 0.826
Cerebrovascular disease 98 (12.7) 75 (12.8) 23 (12.5) 0.202 60 (13.0) 38 (12.2) 0.453
Congestive heart failure 8 (1.0) 5 (0.9) 3 (1.6) 0.404 3 (0.7) 5 (1.6) 0.279
Laboratory data
Hemoglobin (g/dL) 12.5±2.0 12.8±2.0 11.6±1.7 <0.001 12.9±2.0 11.9±1.8 <0.001
Blood urea nitrogen (mg/dL) 31.5±16.4 29.9±15.7 36.5±17.6 <0.001 28.8±14.7 35.5±18.0 <0.001
Creatinine (mg/dL) 1.1±0.5 1.2±0.5 1.0±0.5 0.002 1.1±0.5 1.1±0.5 0.549
Cystatin C (mg/L) 1.8±0.8 1.7±0.8 2.2± 0.9 <0.001 1.7±0.6 2.1±0.9 <0.001
Uric acid (mg/dL) 7.3±1.9 7.3±1.8 7.4±2.0 0.470 7.2±1.8 7.4±2.0 0.107
Calcium (mg/dL) 9.1±0.5 9.1±0.5 9.0±0.5 0.020 9.1±0.5 9.1±0.5 0.393
Phosphate (mg/dL) 3.7±0.7 3.7±0.7 3.9±0.6 0.001 3.6±0.7 3.9±0.7 <0.001
Albumin (g/dL) 4.2±0.4 4.2±0.4 4.1±0.4 0.415 4.2±0.4 4.2±0.4 0.936
Total cholesterol (mg/dL) 170.0±35.7 169.7±34.9 170.8±38.0 0.717 168.4±34.4 172.3±36.6 0.139
Intact parathyroid hormone (pg/mL) 51.5 (32.7–84.8) 48.0 (31.0–77.9) 69.3 (41.5–116.6) <0.001 48.0 (31.2–78.1) 65.4 (40.0–115.9) <0.001
C-reactive protein (mg/dL) 0.1 (0.0–0.2) 0.1 (0.0–0.2) 0.1 (0.0–0.5) 0.585 0.1 (0.0–0.2) 0.1 (0.0–0.7) 0.016
25-hydroxyvitamin D (ng/mL) 18.4±10.0 18.7±9.7 17.1±10.9 0.035 19.7±10.3 17.8±9.5 0.008
1,25-dihydroxyvitamin D (pg/mL) 31.8±17.2 32.8±17.7 27.4±13.9 <0.001 33.6±19.8 28.1±14.9 <0.001
24-hour urine protein (g/day) 0.5 (0.2–1.6) 0.5 (0.2–1.6) 0.6 (0.2–1.5) 0.103 0.6 (0.2–1.7) 0.6 (0.2–1.6) 0.346
24-hour urine creatinine (mg/day) 1168.7±415.0 1277.9±413.5 899.0±299.5 <0.001 1211.5±393.8 973.4±323.4 <0.001
Creatinine clearance (mL/min) 51.2±31.1 55.8±31.7 35.7±23.4 <0.001 58.2±32.3 40.1±25.5 <0.001
CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; Cys, cystatin C; eGFR, estimated glomerular filtration 
rate; MDRD, Modification of Diet in Renal Disease. 
All continuous data are expressed as mean±standard deviation or median (interquartile range) as appropriate. CKD stage is defined using the MDRD eGFR val-
ues: stage 1, ≥90 mL/min/1.73 m2; stage 2, 60–89 mL/min/1.73 m2; stage 3, 30–59 mL/min/1.73 m2; stage 4, 15–29 mL/min/1.73 m2; stage 5, <15 mL/
min/1.73m2. The number of patients who provided 24-hour urine was 736 (94.4%). Conversion factors for units: serum creatinine in mg/dL to μmol/L, ×88.4; 
urea nitrogen in mg/dL to mmol/L, ×0.357.
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cific eGFR equation and the CKD-EPI formula at two pre-de-
fined points are provided in Supplementary Table 4 (only on-
line). The AUC of the CKD-EPI equation was larger than that 
of the Korean-specific and creatinine based eGFR equation, 
and it was also statistically significant.
Propensity score matching analysis data
As shown in Table 1, baseline kidney function was different be-
tween the normal bone mass group and osteopenia group. This 
could be a confounding factor to solidify the effect of cystatin 
C-based equation on osteopenia. For this reason, we con-
ducted 1:1 PSM analysis according to baseline CKD stage. Af-
ter PSM, 185 patients of each group were selected in regard to 
total hip osteopenia, and 312 patients of each group were 
chosen for femur neck osteopenia. Table 4 lists the result after 
PSM analysis, and the AUC of CKD-EPI-Cys was the signifi-
cantly largest among the AUCs of all three equations.
Subgroup analysis according to the gender
A previous study reported gender differences in BMD in the 
elderly.22 Therefore, we performed subgroup analysis to find 
differences according to gender (Table 5). As expected, the 
AUCs of the CKD-EPI-Cys were the biggest among the three 
methods irrespective of gender at both pre-defined points. In 
terms of osteopenia at the total hip, CKD-EPI-Cys was superi-
or to the other formulas in men (vs. MDRD, p=0.003; vs. CKD-
EPI-Cr, p=0.007), but not in women (vs. MDRD, p=0.054; vs. 
Table 2. Multiple Logistic Regression Analysis for Osteopenia with eGFR by the CKD-EPI-Cys Formula
Variables
Model 1 Model 2 Model 3
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Total hip osteopenia
eGFR (CKD-EPI-Cys) (per 1 mL/min/1.73 m2 increase) 0.97 0.97–0.98 <0.001 0.97 0.97–0.98 <0.001 0.98 0.97–0.99 0.004
Age (per 1 year increase) 1.07 1.04–1.10 <0.001 1.08 1.05–1.11 <0.001 1.09 1.06–1.12 <0.001
Female (vs. male) 3.71 2.57–5.37 <0.001 5.00 2.77–9.03 <0.001 4.02 2.15–7.51 <0.001
Body mass index (per 1 kg/m2 increase) 0.82 0.77–0.88 <0.001 0.84 0.78–0.90 <0.001
Current smoker (vs. never-smoker) 1.41 0.67–3.01 0.366 1.47 0.68–3.20 0.326
Former smoker (vs. never-smoker) 1.25 0.68–2.30 0.480 1.17 0.63–2.17 0.628
Hemoglobin (per 1 g/dL increase) 0.87 0.76–1.00 0.045
Calcium (per 1 mg/dL increase) 1.09 0.70–1.68 0.709
Intact parathyroid hormone (per 1 pg/mL increase) 1.00 1.00–1.00 0.350
25-hydroxyvitamin D (per 1 ng/mL increase) 0.98 0.96–1.00 0.047
Femur neck osteopenia
eGFR (CKD-EPI-Cys) (per 1 mL/min/1.73 m2 increase) 0.98 0.97–0.99 <0.001 0.98 0.97–0.99 <0.001 0.98 0.98–0.99 0.001 
Age (per 1 year increase) 1.06 1.03–1.08 <0.001 1.07 1.04–1.09 <0.001 1.08 1.05–1.10 <0.001
Female (vs. male) 3.53 2.54–4.89 <0.001 4.73 2.89–7.74 <0.001 4.12 2.43–6.99 <0.001
Body mass index (per 1 kg/m2 increase) 0.88 0.83–0.93 <0.001 0.88 0.83–0.93 <0.001
Current smoker (vs. never-smoker) 1.45 0.79–2.66 0.229 1.62 0.87–3.02 0.129
Former smoker (vs. never-smoker) 1.40 0.85–2.29 0.185 1.42 0.86–2.35 0.170
Hemoglobin (per 1 g/dL increase) 0.92 0.82–1.03 0.159
Calcium (per 1 mg/dL increase) 1.45 0.99–2.13 0.057
Intact parathyroid hormone (per 1 pg/mL increase) 1.00 1.00–1.01 0.065
25-hydroxyvitamin D (per 1 ng/mL increase) 0.98 0.97–1.00 0.059
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cys, cystatin C; eGFR, estimated glomerular filtration rate; OR, odds ratio.
Table 3. p value of ROC Curves Pairwise Comparisons on Osteopenia at 
the Total Hip and Femur Neck
 MDRD CKD-EPI-Cr CKD-EPI-Cys
Total hip osteopenia
AUC 0.646 0.647 0.678
p value (vs. CKD-EPI-Cys) <0.001 0.001 -
Femur neck osteopenia
AUC 0.645 0.645 0.665
p value (vs. CKD-EPI-Cys) 0.008 0.011 -
AUC, area under the ROC curve; CKD-EPI, Chronic Kidney Disease Epidemiol-
ogy Collaboration; Cr, creatinine; Cys, cystatin C; MDRD, Modification of Diet 
in Renal Disease; ROC, receiver operating characteristic.
Table 4. p value of ROC Curves Pairwise Comparisons on Osteopenia at 
the Total Hip and Femur Neck after 1:1 Propensity Score Matching Ac-
cording to Baseline Chronic Kidney Disease Stage
MDRD CKD-EPI-Cr CKD-EPI-Cys
Total hip osteopenia
AUC 0.508 0.510 0.546
p value (vs. CKD-EPI-Cys) 0.003 0.005 -
Femur neck osteopenia
AUC 0.556 0.557 0.587
p value (vs. CKD-EPI-Cys) <0.001 0.001 -
AUC, area under the ROC curve; CKD-EPI, Chronic Kidney Disease Epidemiol-
ogy Collaboration; Cr, creatinine; Cys, cystatin C; MDRD, Modification of Diet 
in Renal Disease; ROC, receiver operating characteristic.
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CKD-EPI-Cr, p=0.111). However, at the femur neck, CKD-EPI-
Cys was not superior to the other formulas when assessing os-
teopenia in both male and female patients, except when com-
pared to MDRD in males (vs. MDRD, p=0.039).
DISCUSSION
We compared three eGFR formulas used to estimate renal 
function and osteopenia using BMD as a standard, and found 
that CKD-EPI-Cys was the best formula in CKD patients. For 
the first time, we used ROC curve analysis to demonstrate that 
the cystatin C-based eGFR formula was superior to conven-
tional creatinine-based eGFR calculation methods to detect 
osteopenia in CKD patients.
CKD patients experience loss of bone mass accompanied 
by a decline in renal function, and the prevalence of fractures 
has been reported as 18–47% in CKD stage 3 and 42,3 and 30–
52% in ESRD patients.6,23 Bone mass decline has been revealed 
as one of the factors associated with increased fracture risks in 
CKD patients recently, although current guidelines recom-
mend not testing BMD in CKD patients. Therefore, there is an 
unmet clinical need for effective markers for predicting bone 
mass decline in CKD patients. Cystatin C recently came into 
the spotlight as a valid marker for estimating renal function, 
and some studies have reported that cystatin C-based eGFR 
equation is superior to creatinine-based eGFR ones in esti-
mating renal function and predicting cardiovascular events.13-15 
Furthermore, a recent study also proposed cystatin C as a pre-
dictor of hip fracture risk in elderly female patients,17 and sev-
eral previous studies regarding the association between mild 
decreased renal function assessed by cystatin C in the elderly 
and loss of bone mass have also been reported.24-26 However, 
little is known about the relationship between cystatin C and 
decreased bone mass determined by BMD in CKD patients, 
and further research is needed on this patient group.
We measured BMD using DXA in all patients at enrollment, 
and the results were analyzed by three eGFR formulas. As 
mentioned earlier, the Kidney Disease Improving Global Out-
comes CKD-MBD guidelines recommend that BMD testing 
should not be performed routinely, because BMD cannot pre-
dict fracture risks and the type of renal osteodystrophy in CKD 
patients.5 However, several reports on general populations 
with mild renal function decline and bone loss,1,24,26 and recent 
studies with CKD patients have demonstrated contrasting re-
sults: BMD can predict fracture risk in patients with CKD.8,9,27 
Considering the invasiveness of bone biopsy, BMD assess-
ment can be an effective method to predict fracture risk in 
CKD patients.
In this study, CKD-EPI-Cys had the largest AUC among the 
three eGFR calculation methods for reflecting osteopenia in 
CKD patients. In contrast to CKD-EPI-Cys, eGFR calculated 
using creatinine (MDRD and CKD-EPI-Cr) showed discrep-
ancies between the two BMD measurement sites in reflecting 
osteopenia. All of these results consistently support the supe-
riority of cystatin C-based eGFR formula over creatinine-
based eGFR formulas for detecting osteopenia in CKD pa-
tients. A previous study on women without clinical CKD 
(eGFR ≥60 mL/min/1.73 m2) demonstrated a relationship be-
tween increased risk of hip fracture and higher cystatin C lev-
els, but not higher serum creatinine levels.17 We suggest that 
early changes in bone metabolism due to mild deterioration 
of renal function, including changes in calcium, phosphorus, 
and vitamin D homeostasis, cannot be easily detected by se-
rum creatinine changes and that cystatin C could reflect these 
changes earlier than serum creatinine. We also suggest that 
individual muscle mass variations can hinder the accuracy of 
creatinine-based eGFR calculation methods. In patients with 
low muscle mass, creatinine-based eGFR might overestimate 
renal function, compared to measured GFR. Therefore, creati-
nine-based eGFR formulas cannot accurately reflect renal 
function in patients with low muscle mass. Finally, cystatin C 
is not only implicated in renal function, but also has consider-
able extrarenal effects that can impact outcomes.15,28 Therefore, 
other underlying mechanisms of cystatin C, such as interaction 
with inflammatory factors and direct effects on bone resorp-
tion,16,29,30 might explain why cystatin C is particularly effective 
in predicting bone mass changes in CKD patients.
In addition, gender subgroup analysis showed that CKD-
EPI-Cys was not statistically significantly associated with os-
teopenia in female patients. The most plausible explanation 
for this is the relatively small number of the female patients 
included in the study. Nevertheless, we also speculate that the 
effect of menopause in females aged >50 years may play an 
Table 5. p value of ROC Curve Pairwise Comparisons/Subgroup Analysis According to Gender
Male MDRD CKD-EPI-Cr CKD-EPI-Cys Female MDRD CKD-EPI-Cr CKD-EPI-Cys
Total hip osteopenia
AUC 0.655 0.658 0.693 AUC 0.637 0.642 0.666
p value (CKD-EPI-Cys) 0.003 0.007 - p value (CKD-EPI-Cys) 0.054 0.111 -
Femur neck osteopenia
AUC 0.657 0.662 0.679 AUC 0.628 0.633 0.649
p value (CKD-EPI-Cys) 0.039 0.101 - p value (CKD-EPI-Cys) 0.113 0.211 -
AUC, area under the ROC curve; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; Cys, cystatin C; MDRD, Modification of Diet in Re-
nal Disease; ROC, receiver operating characteristic.
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important role in BMD changes, making it hard to diagnose 
osteopenia by CKD-EPI-Cys alone. Therefore, additional in-
vestigations combining the effects of menopause and renal 
function decline are needed to predict bone mass changes in 
elderly female CKD patients.
Bone quantity and quality are the main factors contributing 
to bone force, and bone quantity decline has an additive ef-
fect on increasing fracture risk in CKD-MBD patients. The 
evaluation of bone quality by bone biopsy is a proven-diag-
nostic method to predict fracture risks in CKD-MBD patients.5 
Therefore, high-risk patients need to be assessed for fracture 
earlier with respect to decreased bone mass, and using cystatin 
C to accurately assess renal function and predict skeletal events 
could be a useful tool in CKD patients.
This study has several limitations. First, we did not directly 
measure GFR, and thus, we could not compare eGFR with ac-
curately measured GFR. Second, we could not obtain data 
about menopause, fracture history, and medication history, 
such as steroid use, as well as data about Z-score and mea-
sured BMD values, muscle and lean body mass, and bone 
turnover markers. Due to these shortcomings, exclusion of 
the patients aged less than 50 years old may affect the results 
of this study. Third, this is a cross sectional study, and we did 
not check the incidence of fracture or serial BMD changes. Al-
though our findings demonstrated an important aspect of de-
terioration of renal function and low BMD, future investiga-
tions taking into account fracture incidence data are needed. 
Despite these caveats, this study emphasizes, for the first time, 
the importance of cystatin C-based eGFR in the detection of 
bone mass decline in CKD patients, and may provide clinical 
evidence that calls for early detection strategies to prevent loss 
of bone mass and fracture risks in CKD patients with cystatin 
C measurement.
In conclusion, deterioration of renal function assessed by 
CKD-EPI-Cys correlates with osteopenia better than eGFR 
calculated using creatinine-based methods in CKD patients. 
CKD-EPI-Cys is the most powerful method for detecting os-
teopenia among three eGFR formulas tested, suggesting it 
might be a useful tool for assessing the risk of skeletal events 
in CKD patients.
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